Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts

Carrie E. Pierce, Khaled Bouri, Carol Pamer, Scott Proestel, Harold W. Rodriguez, Hoa Le, Clark C. Freifeld, John S. Brownstein, Mark Walderhaug, I. Ralph Edwards and Nabarun Dasgupta ()
Additional contact information
Carrie E. Pierce: Epidemico, Inc.
Khaled Bouri: US Food and Drug Administration
Carol Pamer: US Food and Drug Administration
Scott Proestel: US Food and Drug Administration
Harold W. Rodriguez: Epidemico, Inc.
Hoa Le: Epidemico, Inc.
Clark C. Freifeld: Epidemico, Inc.
John S. Brownstein: Epidemico, Inc.
Mark Walderhaug: US Food and Drug Administration
I. Ralph Edwards: WHO Collaborating Centre for International Drug Monitoring
Nabarun Dasgupta: Epidemico, Inc.

Drug Safety, 2017, vol. 40, issue 4, No 5, 317-331

Abstract: Abstract Introduction The rapid expansion of the Internet and computing power in recent years has opened up the possibility of using social media for pharmacovigilance. While this general concept has been proposed by many, central questions remain as to whether social media can provide earlier warnings for rare and serious events than traditional signal detection from spontaneous report data. Objective Our objective was to examine whether specific product–adverse event pairs were reported via social media before being reported to the US FDA Adverse Event Reporting System (FAERS). Methods A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug–event pair level with six negative controls. Social media data corresponding to two years prior to signal detection of each product–event pair were compiled. Automated classifiers were used to identify each ‘post with resemblance to an adverse event’ (Proto-AE), among English language posts. A custom dictionary was used to translate Internet vernacular into Medical Dictionary for Regulatory Activities (MedDRA®) Preferred Terms. Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria. Cases were also compared with those reported in FAERS. Findings A total of 935,246 posts were harvested from Facebook and Twitter, from March 2009 through October 2014. The automated classifier identified 98,252 Proto-AEs. Of these, 13 posts were selected for causality assessment of product–event pairs. Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product–event associations: dronedarone–vasculitis and Banana Boat Sunscreen--skin burns. No product–event associations were found among the negative controls. In one of the positive cases, the first report occurred in social media prior to signal detection from FAERS, whereas the other case occurred first in FAERS. Conclusions An efficient semi-automated approach to social media monitoring may provide earlier insights into certain adverse events. More work is needed to elaborate additional uses for social media data in pharmacovigilance and to determine how they can be applied by regulatory agencies.

Keywords: Social Media; Progressive Multifocal Leukoencephalopathy; Ziprasidone; Safety Signal; Dronedarone (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (7)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-016-0491-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:4:d:10.1007_s40264-016-0491-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-016-0491-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().